Chronic obstructive pulmonary disease (COPD) is a complex disease that is predicted to be the third most common cause of death by 2030. In Canada, the care and management of chronic conditions is largely provided by primary care providers. Although there is emerging research and initiatives that describe the prevalence of COPD in Canadian primary care settings, to our knowledge, there have been no efforts to use a large pan-Canadian database to analyze COPD as a risk factor for other common chronic conditions managed in primary care. We report the risk of developing comorbidities after the onset of COPD, that is, the extent to which COPD is a risk factor for developing common chronic conditions (heart failure, depression, anxiety, coronary artery disease, diabetes, anemia, hypertension, ischemic heart disease, underweight, and osteoporosis). After adjusting for age, sex, urban vs rural residence, and smoking status, the relative risks for patients with COPD at baseline were significantly higher for subsequent incidence of anemia, anxiety, diabetes, depression, heart failure, ischemic heart disease, lung cancer, osteoporosis, sleep apnea, underweight, and hypertension than patients without COPD. Using a cut-point of a 200% increase in relative risk as indicative of particular clinical relevance, COPD has a statistically and clinically significant association with developing lung cancer, becoming underweight, and developing heart failure.

ARTICLE OPEN

Chronic obstructive pulmonary disease as a risk factor in primary care: a Canadian retrospective cohort study

Andrew Cave1✉, Anh Pham2, Cliff Lindeman1,2, Boglarka Soos3, Tyler Williamson3 and Neil Drummond1,3

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a common condition worldwide. In Canada, it is more common in men than women and has a prevalence estimate in patients over the age of 40 years of approximately 6%. It is associated with a variety of comorbidities that have an adverse effect on mortality and direct and indirect health care costs. Some people believe that COPD and many of the associated conditions such as diabetes and coronary heart disease share a common inflammatory origin. Several authors have described the prevalence and odds ratios (ORs) of conditions associated with COPD. Less is known about the risk of developing comorbidities after the onset of COPD, that is, the extent to which COPD is a risk factor for developing those conditions. Hence, we considered conditions that the literature indicated are associated with COPD and determined their rate of onset after diagnosis of the latter. Conditions selected for study had to have been reported as being associated with COPD and also available for analysis in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) dataset. For example, “frailty” is often reported as being associated with COPD; however, CPCSSN does not have a valid frailty definition and the condition was therefore not included in this analysis.

RESULTS

Of the 960,652 patients over the age of 40 years in the national CPCSSN as of December 31, 2017, 139,414 (14.5%) had complete age, sex, postal code (i.e., Forward Sortation Area (FSA)) and smoking data (free text) extracted from family physicians’ electronic medical records (EMR) after January 1, 1990, and at least 5 years of data (January 1, 2013–December 31, 2017). Of these, 4629 (3.3%) patients had a COPD diagnosis (by CPCSSN validated definition) prior to baseline (January 1, 2013) (Fig. 1).

Table 2 presents the adjusted and unadjusted relative risks (RRs) for incident diagnosis of anemia, anxiety, diabetes, depression, heart failure, hypertension, ischemic heart disease, lung cancer, osteoporosis, sleep apnea, and being underweight (body mass index <18.5) in COPD patients compared to non-COPD patients. The RRs were adjusted for patient age, sex, smoking status, and rurality. The adjusted RRs for patients with COPD at baseline were significantly higher for subsequent incidence of anemia (RR = 1.55; 95% confidence interval (CI) 1.44–1.67; p < 0.001), anxiety (RR = 1.34; 95% CI 1.28–1.41; p < 0.001), diabetes (RR = 1.15; 95% CI 1.09–1.22; p < 0.001), depression (RR = 1.68; 95% CI 1.59–1.76; p < 0.001), heart failure (RR = 2.64; 95% CI 2.40–2.90; p < 0.001), ischemic heart disease (RR = 1.44; 95% CI 1.35–1.55; p < 0.001), lung cancer (RR = 7.57; 95% CI 4.74–12.09; p < 0.001), osteoporosis (RR = 1.34; 95% CI 1.25–1.44; p < 0.001), sleep apnea (RR = 1.82; 95% CI 1.56–2.12; p < 0.001), being underweight (RR = 4.23; 95% CI 3.44–5.20; p < 0.001), and hypertension (RR = 1.10; 95% CI 1.06–1.16; p = 0.199).

Published in partnership with Primary Care Respiratory Society UK
COPD was associated with increased RR for developing all of the conditions that we had drawn from the literature. Soriano et al. reported a RR of 3.14 (95% CI 2.3 – 4.0) for osteoporosis (ours was 1.34 (95% CI 1.25 – 1.44); see Table 2). He also reported RR 1.75 (95% CI 1.2 – 2.5) for myocardial infarction and 1.67 (95% CI 1.4 – 2.0) for angina. These may be compared to our use of the term “ischemic heart disease” (RR 1.44; 95% CI 1.35 – 1.55) and to the term “cardiovascular disease” used by Mannino et al. (OR 2.4; 95% CI 1.9 – 3.0). The latter also concluded that OR increased with the severity of COPD.

The risks for lung cancer, becoming underweight, and heart failure, RR = 7.57, 4.23, and 2.64 (p < 0.001), were particularly evident in our findings. The high risk of developing lung cancer may be due to the common causative factor, smoking, though we adjusted for smoking as a possible confounder in the analysis, suggesting that a more nuanced interpretation may be required. Becoming underweight may itself be indicative of developing general frailty. Incident heart failure may similarly be indicative of multiple clinical system failure.

The American Academy of Family Physicians and the College of Family Physicians of Canada could not find strong enough evidence to support routine screening for lung cancer by low-dose computed tomography (LDCT) but, with a RR of 7.57, screening COPD patients for lung cancer might be considered to be indicated. The American Thoracic Society, the American Lung Association, and others recommend LDCT for high-risk patients who are aged 55 – 74 years and have a smoking history of 30 pack years based on the National Lung Screening Study. This is reflected in the United States Prevention Strategies Task Force 2013 recommendation, which also includes current smokers (age 55 – 80 years) or those who smoked in the past 15 years. Screening other groups is not recommended. The National Comprehensive Cancer Network 2014 suggest screening be extended to those who have a “personal history of lung disease: COPD, pulmonary fibrosis,” and the Mayo clinic suggest “people with other risk factors for lung cancer” should be screened. Our findings suggest that patients with COPD should be included in that group and have LDCT to detect early lung cancer while it is still treatable. While heart failure is always considered clinically as a differential diagnosis and comorbidity in COPD, the RR of osteoporosis we found would only weakly support the screening of COPD patients for osteoporosis but should raise clinician awareness of the increased risk of fractures.

**METHODS**

**Study design**

This was a retrospective cohort study of patients with COPD receiving primary care in Canada between January 1, 2013 and December 31, 2017. Case definitions for COPD and comorbidities were derived from already validated case definitions, from International Classification of Disease-9 codes recorded in billing, encounter diagnosis, or health condition/problem list tables in the EMRs, and from measurements such as body mass index. Table 3 lists the origin of each case definition. For reference, details of validated CPCSSN case definitions can be found at http://cpcssn.ca/wp-content/uploads/2014/07/CPCSSN_DiseaseDefinitionsFINAL_July16-2014.pdf.

To ensure a robust study design with demographic information relevant to COPD and chronic disease comorbidities managed in primary care, strict requirements were enforced. To be included in the analysis, patients’ records must have included data for age, sex, FSA (to determine whether a patient lived in a rural or urban setting), smoking status (any instance of smoking behavior, whether light or heavy, current or past, deemed the patient as a lifetime “smoker” for the purposes of this analysis), and at least one primary care clinic encounter in 2013 and at least one in 2017. The baseline date (where the categorization of patients as COPD or non-COPD was made) was selected to ensure that there was a 5-year window when patients could present their first instance of a comorbidity. Without that restriction, there may have been an uneven distribution of time for patients to experience a comorbidity onset.

**DISCUSSION**

In Canada, many patients with COPD are never seen in secondary care and only managed in primary care. Based on a retrospective cohort study of primary care physician’s records, results showed that the elderly, males, and current or past smokers were more likely to develop COPD than those who are younger, female, or those who have never smoked. COPD onset had a statistically significant association with all outcomes of interest. However, using a cut-point of a 200% increase in RR as indicative of significant association with COPD at baseline (n = 4629) and from measurements such as body mass index. Table 3 lists the origin of each case definition. For reference, details of validated CPCSSN case definitions can be found at http://cpcssn.ca/wp-content/uploads/2014/07/CPCSSN_DiseaseDefinitionsFINAL_July16-2014.pdf. Without that restriction, there may have been an uneven distribution of time for patients to experience a comorbidity onset.

**Fig. 1 Derivation of Data for Analysis.** Canadian Primary Care Sentinel Surveillance Network (CPCSSN), FSA (Forward Sortation Area), COPD (Chronic Obstructive Pulmonary Disease). Data available for analysis.

**Table 1. Demographic characteristics.**

|                | COPD at baseline (n = 4629) | Non-COPD at baseline (n = 128,342) | Test of significance |
|----------------|-----------------------------|-----------------------------------|----------------------|
| Age (±SD)      | 62.8 (11.2)                 | 55.8 (10.9)                       | t test (p < 0.001)   |
| Female (%)     | 2405 (52.0)                 | 74,341 (57.9)                    | Chi² (p < 0.001)     |
| Urban (%)      | 4149 (89.6)                 | 114,981 (89.6)                   | Chi² (p = 0.008)     |
| Smokers (%)    | 4175 (90.2)                 | 89,943 (70.1)                    | Chi² (p < 0.001)     |

CPCSSN 2017 has 960,652 patients aged ≥40 years

CPCSSN patients aged ≥40 years, with age, sex, FSA, and 5 years of data N = 139,414

Exclude patients with COPD after baseline (n = 6443)

Eligible patients N = 132,971

Patients with COPD N = 4829

Patients without COPD N = 128,342

Published in partnership with Primary Care Respiratory Society UK
Table 2. Relative risk for patients exposed to COPD compared to patients unexposed to COPD.

| Comorbidity                | Comorbidity incidence after baseline (%) | Unadjusted results | Adjusted results |
|----------------------------|------------------------------------------|--------------------|------------------|
|                            |                                          | RR     | p value | Lower 95% CI | Upper 95% CI | ARR* | p value | Lower 95% CI | Upper 95% CI |
| Anemia                     | 10,322 (7.8)                            | 1.82   | <0.001 | 1.69       | 1.96       | 1.55 | <0.001 | 1.44       | 1.67       |
| Anxiety                    | 32,853 (25.9)                           | 1.20   | <0.001 | 0.97       | 1.08       | 1.34 | <0.001 | 1.28       | 1.41       |
| Diabetes                   | 20,533 (16.1)                           | 1.45   | <0.001 | 1.39       | 1.53       | 1.15 | <0.001 | 1.09       | 1.22       |
| Depression                 | 21,003 (16.3)                           | 1.63   | <0.001 | 1.55       | 1.71       | 1.68 | <0.001 | 1.59       | 1.76       |
| Heart failure              | 3527 (2.7)                              | 4.77   | <0.001 | 4.36       | 5.20       | 2.64 | <0.001 | 2.40       | 2.90       |
| Hypertension               | 43,043 (35.5)                           | 1.45   | <0.001 | 1.40       | 1.49       | 1.10 | <0.001 | 1.06       | 1.16       |
| Ischemic heart disease     | 12,237 (9.4)                            | 2.19   | <0.001 | 2.06       | 2.33       | 1.44 | <0.001 | 1.35       | 1.55       |
| Lung cancer                | 90 (0.07)                               | 11.89  | <0.001 | 7.58       | 18.65      | 7.57  | <0.001 | 4.74       | 12.09      |
| Osteoporosis               | 13,421 (10.3)                           | 1.81   | <0.001 | 1.70       | 1.93       | 1.34 | <0.001 | 1.25       | 1.44       |
| Sleep apnea                | 2734 (2.1)                              | 1.81   | <0.001 | 1.55       | 2.11       | 1.82  | <0.001 | 1.56       | 2.12       |
| Underweight C              | 834 (0.8)                               | 4.12   | <0.001 | 3.38       | 5.04       | 4.23  | <0.001 | 3.44       | 5.20       |

*Relative risk for patients exposed to COPD compared to patients not exposed to COPD (adjusted for: age, sex, smoking status, and urban/rural postal code). bPoisson distribution was applied and incidence rate ratios (IRRs) were produced instead of relative risk (RR).

The study was granted approval by the University of Alberta, Research Ethics Office Pro:00079146.

Table 3. Comorbidity case definitions.

| Comorbidity       | ICD-9 code(s)          |
|-------------------|------------------------|
| Anemia            | 280–285                |
| Anxiety           | 300                    |
| COPD              | CPCSSN case definition |
| Diabetes          | CPCSSN case definition |
| Depression        | CPCSSN case definition |
| Heart failure     | 428                    |
| Hypertension      | CPCSSN case definition |
| Ischemic heart disease | 410–414               |
| Lung cancer       | 162                    |
| Osteoporosis      | 733, 737.40–737.43, 737.7, 731.0 |
| Sleep apnea       | 327.2, 780.51, 780.53, 780.57 |
| Underweight C     | BMI between 5.0 and 18.5 (CPCSSN excludes BMI inputs <5.0 as an assumed error) |

Data source

The CPCSSN database contains information from ten primary care research networks across the country; over 1300 participating primary care “sentinel” clinicians contribute data on >1,800,000 patients in 8 provinces and territories.18 Primary care providers agree to have their EMR information extracted on a bi-annual basis for health services research, quality improvement, and disease surveillance purposes. To ensure patient and provider anonymity, patient and health care provider identifying data are removed at the time of data extraction and processing.

Statistical analysis

We calculated the statistical differences in demographic data for patients with COPD at baseline compared to those without. Frequencies, means, and standard deviations are presented for continuous variables. Frequencies and percentages are presented for categorical variables.

Further, we calculated crude RRs for patients having COPD at baseline compared to patients without COPD, as well as RR adjusting for age, sex, smoking status, and urban/rural residence. The incidence of comorbidities was measured in those with COPD at baseline and in those without COPD at baseline during the 5-year follow-up period. When the binomial Generalized Linear Model was not concave, even after using mI and irIs options to optimize the deviance, Poisson distribution was applied to estimate RRs. Analyses were conducted with Stata 16.

Study limitations

This study is limited to the data available in individual primary care providers’ EMR. If a patient is new to a CPCSSN sentinel, it is possible that there is no data for that individual prior to their first encounter with that provider, thereby limiting the inclusion of data for the analysis. CPCSSN data does not include hospital-recorded information, limiting data to care received from their sentinel primary care provider alone.

CPCSSN has a validated algorithm for identifying conditions including COPD but not for all the comorbidities we examined (see Table 3). As a result, there may be variation in the misclassification rate due to physician diagnosis error and recording error among the comorbidities being considered. However, we anticipate no difference based on the COPD status of the patient. Further, some conditions may take many years to develop after COPD diagnosis and our cohort may not have continued long enough for them to present (e.g., CHD or anemia). In this latter case, the anemia of chronic disease may be offset by the anoxic drive toward polycythemia. However, the use of primary care data is also a strength of the study, in that it derives from a population which is representative of the population at large. Most COPD patients are managed in primary care only and so our results are highly relevant to this population.

This study assumed the first disease-specific record in the EMR data as identifying the incidence of a given condition and the order in which they developed. Due to differing latent periods, there is potential for error in disease indication. Further, CPCSSN case definitions do not have 100% sensitivity, and there therefore is a potential for the inclusion of false positive cases. Williamson et al. developed the case definitions with a utility threshold of 70%; case definitions that meet at least 70% sensitivity, specificity, positive predictive value, and negative predictive value are considered valid and sufficient for epidemiological studies. We caution readers to potential misclassification of outcome. Spirometry results were not available to confirm the diagnosis of COPD.

Lastly, only 14.5% of patients in the database were included in the cohort for analysis (Fig. 1). By insisting that all the cohort had complete data for the whole study period, we reduced the size of the cohort but...
increased its validity. We examined the cohort and found that it was comparable to its base population in terms of age, gender, and smoking.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

The data that support the findings are available through a CPCSSN application process. Contact https://cpcssn.ca for more information.

Received: 3 April 2020; Accepted: 24 May 2021; Published online: 24 June 2021

**REFERENCES**

1. Halbert, R. J. et al. Global burden of COPD: systematic review and meta-analysis. *Eur. Respir. J.* **28**, 523–532 (2006).
2. Adeloye, D. et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. *J. Glob. Health* **5**, 020445 (2015).
3. Green, M. E. et al. Chronic obstructive pulmonary disease in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance Network. *Can. Med. Assoc. J.* **185**, E15–E22 (2015).
4. Theriault, L., Hermus, G., Goldfarb, D., Stonebridge, C., & Bounajm, F. Cost risk analysis for chronic lung disease in Canada. Conference Board of Canada. https://www.conferenceboard.ca/temp/b10c7b7b-71c9-42fb-9146-f36e66d21ee3/12-114_CostRiskAnalysisv4.pdf (2012).
5. O’Donnell, D. E. et al. Canadian Thoracic Society guidelines for the management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. *Can. Respir. J.* https://doi.org/10.1155/2008/641965 (2008).
6. Sawatha, S. et al. The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study. *Ther. Adv. Respir. Dis.* **13**, 1–10 (2019).
7. Lisspers, K. et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. *Int. J. Chron. Obstr. Pulm. Dis.* **13**, 275–285 (2018).
8. Patel, J. G., Nagar, S. P., & Dalal, A. A. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. *Int. J. Chron. Obstruct. Pulmon. Dis.* **9**, 289–300 (2014).
9. Iheanacho, I., Zhang, S., King, D., Rizzo, M., & Ismaila, A. S. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. *Int. J. Chron. Obstruct. Pulmon. Dis.* **15**, 439–460 (2020).
10. Divo, M. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **186**, 155–161 (2012).
11. Chetty, U. et al. COPD and comorbidities: a cross sectional analysis of 1.2 million patients from a nationally representative dataset in Scotland. https://sapc.ac.uk/conference/2016/abstract/copd-and-comorbidities-cross-sectional-analysis-of-1-2-million-patients (2016).
12. Smith, M. C. & Wrobel, J. P. Epidemiology and clinical impact of major comorbidities in newly diagnosed COPD and asthma in primary care. *Can. Respir. J.* **10**, 2099–2107 (2005).
13. Mannino, D. M., Thorn, D., Swensen, A. & Holguin, F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur. Respir. J.* **32**, 962–969 (2008).
14. Hsu, W.-L., Chen, H.-Y., Chang, F.-W. & Hsu, R.-J. Does chronic obstructive pulmonary disease increase the risk of prostate cancer? A nationwide population-based study. *Int. J. Chron. Obstruct. Pulmon. Dis.* **14**, 1913–1921 (2019).
15. Putcha, N., Drummond, M. B., Wise, R. A. & Hansel, N. N. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. *Semin. Respir. Crit. Care Med.* **36**, 575–591 (2016).
16. CPCSSN. Canadian Primary Care Sentinel Surveillance Network. http://cpcssn.ca (2019).

**AUTHOR CONTRIBUTIONS**

A Catalyst Grant from the Canadian Lung Association funded this work.

**ACKNOWLEDGEMENTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41555-021-00249-5.

**Correspondence** and requests for materials should be addressed to A.C.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021.